Wanbury

Has Wanbury declared dividend?

Yes, Wanbury Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 29, 2010. However, the dividend yield is 0%, indicating that returns have primarily come from price appreciation rather than dividend income.

Wanbury Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Jul-29-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 5.38%, the dividend return was 0%, resulting in a total return of 5.38%.<BR><BR>In the 1-year period, the price return was 103.38%, the dividend return was 0%, resulting in a total return of 103.38%.<BR><BR>In the 2-year period, the price return was 420.47%, the dividend return was 0%, resulting in a total return of 420.47%.<BR><BR>In the 3-year period, the price return was 337.36%, the dividend return was 0%, resulting in a total return of 337.36%.<BR><BR>In the 4-year period, the price return was 179.36%, the dividend return was 0%, resulting in a total return of 179.36%.<BR><BR>In the 5-year period, the price return was 1328.57%, the dividend return was 0%, resulting in a total return of 1328.57%.<BR><BR>Overall, while Wanbury Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns have primarily come from price appreciation rather than dividend income. The total returns over various periods show significant growth, particularly over the longer term.

Who are the peers of the Wanbury?

Wanbury's peers include Themis Medicare, Lincoln Pharma, Bharat Parenter, Shukra Pharma, NGL Fine Chem, Kopran, Kilitch Drugs, Shree Ganesh Rem, Remus Pharma, and Sakar Healthcare. Wanbury has average management risk and growth, with a 1-year return of 41.93%, while Shukra Pharma leads with a 146.07% return.

Peers: Themis Medicare, Lincoln Pharma., Bharat Parenter., Shukra Pharma., NGL Fine Chem, Kopran, Kilitch Drugs, Shree Ganesh Rem, Remus Pharma., Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Lincoln Pharma. and NGL Fine Chem, while Average management risk is found at Themis Medicare, Bharat Parenter., Shukra Pharma., Wanbury, Kopran, Shree Ganesh Rem, Remus Pharma., and Sakar Healthcare. Below Average management risk is noted at Kilitch Drugs. Growth is Excellent at Kilitch Drugs and Shukra Pharma., while Average growth is seen at Wanbury, Shree Ganesh Rem, and the rest. Below Average growth is found at Themis Medicare, Lincoln Pharma., Bharat Parenter., NGL Fine Chem, Kopran, and Sakar Healthcare. Capital Structure is Excellent at Lincoln Pharma. and Shree Ganesh Rem, Good at Themis Medicare, Shukra Pharma., Kopran, and Kilitch Drugs, Average at Bharat Parenter. and Sakar Healthcare, and Below Average at Wanbury.<BR><BR>Return Snapshot: Shukra Pharma. has the highest 1-year return at 146.07%, while NGL Fine Chem has the lowest at -47.08%. Wanbury's 1-year return of 41.93% is significantly higher than NGL Fine Chem's but lower than Shukra Pharma's. Additionally, NGL Fine Chem, Kopran, Shree Ganesh Rem, and Sakar Healthcare have negative six-month returns.

Who are in the management team of Wanbury?

As of March 2022, the management team of Wanbury includes N K Puri (Independent Director), K Chandran (Vice Chairman & Whole Time Director), Jitendra J Gandhi (Company Secretary & Compliance Officer), and several Independent Directors: Pallavi Shedge, Binod Chandra Maharana, Manisha Juvekar, Anupam Vaidya, and Pravin Dilip Pawar.

As of March 2022, the management team of Wanbury includes the following individuals:<BR><BR>1. N K Puri - Independent Director<BR>2. K Chandran - Vice Chairman & Whole Time Director<BR>3. Jitendra J Gandhi - Company Secretary & Compliance Officer<BR>4. Pallavi Shedge - Independent Director<BR>5. Binod Chandra Maharana - Independent Director<BR>6. Manisha Juvekar - Independent Director<BR>7. Anupam Vaidya - Independent Director<BR>8. Pravin Dilip Pawar - Independent Director<BR><BR>These members play various roles within the company's governance structure.

What does Wanbury do?

Wanbury Ltd is a Micro Cap pharmaceutical company involved in related activities, reporting net sales of 1,720 Cr and a net profit of 203 Cr for March 2025. It was incorporated in 1988 and has a market cap of INR 893 Cr.

Overview:<BR>Wanbury Ltd is engaged in pharmaceutical and related activities, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1988, Wanbury Ltd was formerly known as Pearl Organics Limited. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,720 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 203 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 893 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 29.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.77 <BR>Return on Equity: 51.53% <BR>Price to Book: 14.98 <BR><BR>Contact Details:<BR>Address: BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-67942222 <BR>Email: shares@wanbury.com <BR>Website: http://www.wanbury.com

Who are the top shareholders of the Wanbury?

The top shareholders of Wanbury include Expert Chemicals (India) Pvt Ltd with 30.53%, individual investors with 41.78%, and public shareholder Suresh Bhatia at 3.58%. Additionally, 7 Foreign Institutional Investors hold 1.55%, while pledged promoter holdings are at 76.74%.

The top shareholders of Wanbury include a mix of promoters and individual investors. The largest promoter is Expert Chemicals (India) Pvt Ltd, holding 30.53% of the shares. Additionally, individual investors collectively hold 41.78% of the company. The highest public shareholder is Suresh Bhatia, who owns 3.58%. There are also 7 Foreign Institutional Investors (FIIs) with a combined holding of 1.55%, while mutual funds currently do not hold any shares in the company. The pledged promoter holdings stand at 76.7355%.

How big is Wanbury?

As of 24th July, Wanbury Ltd has a market capitalization of 851.00 Cr, with recent net sales of 597.75 Cr and a net profit of 30.54 Cr. The balance sheet for March 2024 shows shareholder's funds of 27.94 Cr and total assets of 337.99 Cr.

As of 24th July, Wanbury Ltd has a market capitalization of 851.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Wanbury reported Net Sales of 597.75 Cr and a Net Profit of 30.54 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 27.94 Cr and Total Assets of 337.99 Cr.

Are Wanbury latest results good or bad?

Wanbury's latest results show strong annual growth, with a 118.3% increase in Profit Before Tax and a 23.90% rise in net sales. However, recent quarter-on-quarter declines in net sales and profit raise concerns, leading to a cautious outlook.

Wanbury's latest results present a mixed picture. On one hand, the company has shown significant growth in key financial metrics compared to previous quarters. For the quarter ending June 2025, Wanbury reported a Profit Before Tax (PBT) of Rs 13.26 crore, which is an impressive increase of 118.3% compared to the average PBT from the prior four quarters. Similarly, the Profit After Tax (PAT) rose by 76.7% to Rs 13.49 crore.<BR><BR>Additionally, Wanbury's net sales for the latest six months reached Rs 335.18 crore, reflecting a year-on-year growth of 23.90%. The cash and cash equivalents also improved, reaching Rs 12.83 crore, indicating better short-term liquidity.<BR><BR>However, there are concerns regarding the quarter-on-quarter performance. Wanbury experienced a decline in net sales by 5.13% and a significant drop in consolidated net profit by 33.42% compared to the previous quarter. These downward trends in key metrics suggest challenges in maintaining momentum.<BR><BR>Despite the overall positive annual growth, the recent quarter's performance and the 'Sell' call issued by MarketsMOJO indicate that there may be caution warranted regarding the stock. Therefore, while there are strong annual results, the recent quarterly performance raises some red flags.

Is Wanbury overvalued or undervalued?

As of November 6, 2025, Wanbury is considered undervalued with an attractive valuation grade, supported by a PE ratio of 20.53, strong growth potential indicated by a PEG ratio of 0.41, and impressive operational efficiency metrics like a 27.43% ROCE and 51.53% ROE, especially when compared to its more expensive peers like Sun Pharma and Divi's Laboratories.

As of 6 November 2025, the valuation grade for Wanbury has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 20.53, an EV to EBITDA of 11.90, and a PEG ratio of 0.41, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Wanbury's valuation stands out favorably against Sun Pharma Industries, which is considered expensive with a PE ratio of 35.02, and Divi's Laboratories, which is categorized as very expensive with a PE ratio of 79.09. Additionally, while Wanbury's ROCE is an impressive 27.43% and ROE is a remarkable 51.53%, these figures further highlight its operational efficiency and profitability relative to its peers. Despite recent underperformance against the Sensex in the year-to-date period, Wanbury's long-term returns over three and five years significantly outperform the index, reinforcing its attractive valuation.

How has been the historical performance of Wanbury?

Wanbury's historical performance shows growth in net sales and operating income, increasing from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25. However, profitability declined, with profit before tax dropping to 29.55 Cr in Mar'25, and total liabilities rose to 406.88 Cr, indicating mixed financial health.

Answer:<BR>The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health.<BR><BR>Breakdown:<BR>Wanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sheet. Cash flow from operating activities improved to 26.00 Cr in Mar'25 from 4.00 Cr in Mar'24, although cash flow from investing activities showed a significant outflow of -51.00 Cr in Mar'25. Overall, Wanbury's financial performance reflects a mix of growth in sales and operating income, alongside challenges in profitability and increasing liabilities.

Is Wanbury technically bullish or bearish?

As of December 4, 2025, Wanbury's technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and KST, while daily moving averages and monthly indicators also reflect a cautious outlook.

As of 4 December 2025, the technical trend for Wanbury has changed from bearish to mildly bearish. The current technical stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the monthly MACD and Bollinger Bands suggest a mildly bearish outlook. The daily moving averages also reflect a mildly bearish sentiment. The lack of clear signals from the RSI and no trends in Dow Theory and OBV further support the neutral stance in the short term. Overall, the indicators suggest a cautious approach as the stock remains below its previous highs.

When is the next results date for Wanbury Ltd?

The next results date for Wanbury Ltd is 05 February 2026.

The next results date for Wanbury Ltd is scheduled for 05 February 2026.

Should I buy, sell or hold Wanbury Ltd?

Which are the latest news on Wanbury?

Why is Wanbury Ltd falling/rising?

As of 07-Feb, Wanbury Ltd's stock price is falling to 243.80, down 6.84% after a trend reversal. Despite positive long-term growth indicators, high debt levels and pledged shares raise concerns about financial stability, contributing to the stock's decline.

As of 07-Feb, Wanbury Ltd's stock price is falling, currently at 243.80, reflecting a decrease of 17.9 or 6.84%. This decline follows a trend reversal after five consecutive days of gains. The stock has underperformed its sector by 6.04% today and reached an intraday low of Rs 240.65, which is an 8.04% drop. Additionally, there has been a significant decrease in investor participation, with delivery volume falling by 42.55% compared to the five-day average.<BR><BR>Despite some positive long-term growth indicators, such as a 107.56% annual growth rate in operating profit and a 23.90% increase in net sales over the last six months, the company faces challenges. It has a high debt-to-equity ratio of 3.36 times, which raises concerns about its financial stability. Furthermore, 86.67% of promoter shares are pledged, which can exert additional downward pressure on the stock price in a falling market. These factors contribute to the current decline in Wanbury Ltd's stock price.